Less than 10% of individuals who could benefit from obesity jabs including Wegovy are able to get them, caution the World Health Organization as it releases its initial advice on the medications.
Given in excess of 1,000,000,000 people worldwide currently classified as obese, it is calling for increased and just access to these injectable treatments.
Per estimates, more than two billion will be living with obesity by 2030 without intervention.
"Our latest guidance acknowledges that excess weight is a long-term condition that can be treated with comprehensive and lifelong support," stated its chief Tedros Adhanom Ghebreyesus.
Significant expense, insufficient output, and supply-chain constraints are major hurdles to broad access to the jabs that can help people shift considerable weight, says the body.
GLP-1 Therapy Supply Crisis
Even under the present best projected case, the supply of these medications could only cover around 100 million people – fewer than 10% of those who need them, as stated by the WHO.
The guideline encourages governments and firms to expand availability, through strategies including voluntary licensing.
A patent on semaglutide – the primary component of the drug Wegovy – is set to lapse in a number of nations in 2026.
The Way Obesity Jabs Function
The injections mimick a body's own hormone to reduce digestion speed, suppress the appetite and enhance satiety so users reduce food intake.
People usually begin shedding pounds after several weeks of starting on the regular doses.
Research points to patients may put most of the weight back on a year later of halting the drug, because their normal food cravings resume.
To be carrying excess weight increases your chance for experiencing medical conditions, such as type 2 diabetes, heart disease, stroke, and specific malignancies.
Excess weight concerns people in all nations and was responsible for millions of fatalities worldwide in 2024, according to the health agency.
